Orphazyme
Michael Hove is an accomplished business executive with extensive experience in investment and consultancy. Currently serving as CEO of Scandinavian Investment Group A/S since January 2020, Hove leads an investment firm focused on real estate and credit bonds, listed on Nasdaq Copenhagen. Hove also owns and operates MH Investment, an active holding company, and holds key roles as Chairman and Co-owner of Orphazyme A/S, as well as Co-owner and advisor of Symmetry Administration ApS and Hydract. Previously, Hove was Chairman and Co-Owner of Rovsing A/S, and Chairman and Co-Owner of DLH Group. Hove's educational background includes degrees from Copenhagen Business School and certifications in marketing and sales management.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Orphazyme
Danish biopharma company, listed on Nasdaq Copenhagen, with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases.